循环PD-1+CD8+T淋巴细胞动态变化预测NSCLC免疫治疗反应
该研究在94例复发和/或转移性非小细胞肺癌(NSCLC)患者中发现,PD-1抑制剂治疗一周期后循环PD-1+CD8+T淋巴细胞频率下降与持久临床获益(DCB)及更优生存相关,并在54例独立验证队列中得出一致结果。机制上PD-1分子表达抑制肿瘤抗原特异性CD8+T淋巴细胞的效应功能。
要点
- PD-1抑制剂治疗一周期后循环PD-1+CD8+T细胞频率下降提示更可能获得持久临床获益。
- 该动态变化在独立验证队列及NY-ESO-1特异性CD8+T细胞分析中结果一致。
- PD-1分子表达可抑制肿瘤抗原特异性CD8+T淋巴细胞的效应功能。
核心结论
- PD-1抑制剂治疗一周期后循环PD-1+CD8+T淋巴细胞频率下降可预测NSCLC患者的临床与生存获益。
- 该指标有助识别最可能从PD-1抑制剂获益的患者亚组。
研究设计与样本
- 发现队列纳入94例接受PD-1抑制剂治疗的复发和/或转移性NSCLC患者。
- 在治疗前及一周期治疗后采集外周血,用多色流式细胞术分析循环CD8+T淋巴细胞表型。
- 验证队列为前瞻性试验(NCT03486119)中的54例接受PD-1抑制剂治疗的患者。
主要发现
- 循环PD-1+CD8+T淋巴细胞富集效应/记忆亚群,活化与耗竭相关标志物表达升高。
- 一周期治疗后CD8+T淋巴细胞中PD-1+细胞频率下降与更高DCB概率和更优生存相关。
- 肿瘤抗原NY-ESO-1特异性CD8+T淋巴细胞分析及验证队列获得相似结果。
- PD-1分子表达抑制肿瘤抗原特异性CD8+T淋巴细胞的效应功能。
临床怎么用
- 可考虑在PD-1抑制剂治疗一周期后检测循环PD-1+CD8+T淋巴细胞频率变化,辅助预判NSCLC患者的DCB与生存获益。
- 该指标有望用于筛选最可能从PD-1抑制剂获益的患者亚组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The predictive value of immune monitoring with circulating CD8+ T lymphocytes for treatment response to programmed cell death protein 1 (PD-1) inhibitors has not been explored in non-small-cell lung cancer (NSCLC), prompting us to investigate whether dynamic changes in PD-1+CD8+ T lymphocytes have predictive value for durable clinical benefit (DCB) and survival after PD-1 blockade. METHODS: Patients with recurrent and/or metastatic NSCLC treated with PD-1 inhibitors were enrolled (discovery cohort; n = 94). Peripheral blood was obtained immediately before and after one cycle of treatment with PD-1 blockade. Phenotyping of circulating CD8+ T lymphocytes was conducted using multi-colour flow cytometry. Predictive values of dynamic changes in circulating PD-1+CD8+ T lymphocytes during the first cycle were validated in an independent cohort (validation cohort; n = 54) of a prospective trial with a PD-1 inhibitor (NCT03486119). RESULTS: Circulating PD-1+CD8+ T lymphocytes were enriched with effector/memory populations with elevated expression of activation- and exhaustion-related markers. Reduction in the frequency of PD-1+ cells among CD8+ T lymphocytes after one cycle of treatment was associated with a higher probability of DCB and superior survival outcomes in the discovery cohort. Similar results were obtained in the analysis of tumour antigen NY-ESO-1-specific CD8+ T lymphocytes and the validation cohort. Mechanistically, PD-1 molecule expression on CD8+ T lymphocytes suppresses the effector functions of tumour antigen-specific CD8+ T lymphocytes. CONCLUSIONS: Dynamic changes in circulating PD-1+CD8+ T lymphocytes predict clinical, and survival benefit from PD-1 blockade treatment in NSCLC, providing a useful tool to identify patient subgroups who will optimally benefit from PD-1 inhibitors.
引用
- Kim CG, Hong MH, Kim KH, et al. Dynamic changes in circulating PD-1+CD8+ T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer. Eur J Cancer. 2020. PMID: 33302114. doi:10.1016/j.ejca.2020.10.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。